menu search

MRNA / Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback

Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success. Read More
Posted: Apr 12 2023, 12:55
Author Name: Zacks Investment Research
Views: 103060

MRNA News  

Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?

By The Motley Fool
November 4, 2023

Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?

Moderna reported a billion-dollar loss in the third quarter and began downsizing its manufacturing infrastructure to match lower levels of vaccine dem more_horizontal

Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say

By Zacks Investment Research
November 3, 2023

Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth cons more_horizontal

Moderna CEO discusses earnings and how the company aims to break even by 2026

By Yahoo Finance
November 2, 2023

Moderna CEO discusses earnings and how the company aims to break even by 2026

While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its more_horizontal

Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production

By Investopedia
November 2, 2023

Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production

Moderna (MRNA) shares tumbled over 6% Thursday after reporting a steep loss as the drug maker lost sales and cut back on making its COVID-19 vaccine, more_horizontal

Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript

Moderna, Inc. (NASDAQ:MRNA ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Rela more_horizontal

Moderna stock plummets on 3Q loss and weak sales guidance

By Proactive Investors
November 2, 2023

Moderna stock plummets on 3Q loss and weak sales guidance

Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker's weak full-year sales forecast and a significant loss for th more_horizontal

Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots

By CNBC Television
November 2, 2023

Moderna revenue tops expectations, expects to return to sales growth in 2025

By Reuters
November 2, 2023

Moderna revenue tops expectations, expects to return to sales growth in 2025

Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that more_horizontal


Search within

Pages Search Results: